PEG-Coated Extracellular Vesicles for Lung Mucus Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering gene therapy to the lungs, particularly for conditions like cystic fibrosis and lung cancers, face challenges such as the mucus barrier in the lungs, which impedes the penetration of therapeutic agents, and aerosolization of vesicles is hindered by aggregation and high viscosity, leading to inefficient delivery and immune response issues.
Innovation Solution
Aerosolizable compositions of extracellular vesicles from mesenchymal stem cells coated with polyethylene glycol (PEG) that can penetrate mucus and cell membranes, carrying therapeutic cargo like microRNAs and proteins, facilitating targeted delivery to lung tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vesicles are used for gene therapy delivery to the lungs, then therapeutic cargo can be delivered to lung tissues, but the mucus barrier in the lungs impedes penetration of the vesicles
Solution Approach 1:
The patent uses polyethylene glycol (PEG) as an intermediary coating on the vesicle surface to mediate interaction with the mucus barrier. The PEG layer modifies the vesicle surface properties, enabling it to penetrate through the mucus barrier while maintaining cargo delivery capability. This intermediary coating resolves the contradiction by providing a interface that is compatible with both the vesicle core and the mucus environment.
Solution Approach 2:
The patent changes the surface parameters of the vesicles by coating them with PEG, which alters surface charge, hydrophilicity, and steric properties. These parameter changes enable the vesicles to overcome the mucus barrier's adhesive and obstructive properties, improving penetration while maintaining delivery reliability.
2Ease of operation
If vesicles are aerosolized for inhalation delivery, then direct lung targeting is achieved, but aggregation and high viscosity hinder aerosolization
Solution Approach 1:
The PEG coating acts as an intermediary layer that prevents direct vesicle-vesicle interactions that lead to aggregation. By coating the vesicle surface with PEG, the patent creates steric barriers and reduces surface adhesion, enabling the vesicles to remain dispersed in aerosol form while maintaining compositional stability.
Solution Approach 2:
The patent changes the surface parameters of the vesicles by coating them with PEG, which alters surface charge, hydrophilicity, and steric properties. These parameter changes enable the vesicles to overcome the mucus barrier's adhesive and obstructive properties, improving penetration while maintaining delivery reliability.
3Reliability
If viral vectors are used for gene therapy, then gene transfer efficiency can be improved, but immune response and safety concerns arise
Solution Approach 1:
The patent uses extracellular vesicles as disposable, non-integrating delivery vehicles that perform their function and are then cleared by the body. Unlike viral vectors that can integrate into the genome and cause long-term immune responses, these vesicles provide transient gene delivery without persistent safety concerns, eliminating the harmful immune response while maintaining delivery efficiency.
Solution Approach 2:
The patent creates a composite delivery system combining extracellular vesicles (natural origin) with PEG coating (synthetic polymer). This composite structure provides the benefits of natural vesicles (biocompatibility, low immunogenicity) while adding the advantages of PEG (improved circulation, reduced aggregation, enhanced penetration), achieving effective gene delivery without viral vector-related immune responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PEG-coated vesicles effectively bypass the mucus barrier, achieve aerosolization, and enhance cellular uptake, offering a more efficient and targeted therapeutic approach for lung diseases by ensuring the delivery of therapeutic cargo deep into lung tissues.
Implementation Method 1
an aerosolizable composition comprising extracellular vesicles from mesenchymal stem cells (MSCs) having a surface coating of the hydrophilic polymer polyethylene glycol (PEG)
Implementation Method 2
the vesicles carrying a cargo comprising of one or more of a microRNA (miR)... the PEG-coated vesicles effectively bypass the mucus barrier
Implementation Method 3
achieve aerosolization, and enhance cellular uptake, offering a more efficient and targeted therapeutic approach for lung diseases by ensuring the delivery of therapeutic cargo deep into lung tissues
Data Source
AI summary
Vesicles, including exosomes, having a coating of a hydrophilic, neutral polymer such as PEG have an increased ability to form a suspension or colloid compared to uncoated vesicles. This enables the coated vesicles to be used to form aerosol droplets such that a liquid formulation containing vesicles can be used in a nebulizer for inhaled administration thereof. Such coated vesicles are also able to pass through mucus and can deliver their cargo into lung cells. Exosomes from mesenchymal stem cells can deliver additional proteins, miRs, mRNAs and other nucleic acid sequences to lung cells providing a regenerative gene therapy for CF, COPD lung cancer and other lung diseases.